Accuray, a radiation oncology company, has announced that Sir Charles Gairdner Hospital in Perth is the first center in Australia to treat a brain metastasis patient with its latest generation CyberKnife M6 system.
The company claims that its CyberKnife M6 system provides clinicians with an enhanced stereotactic radiosurgery/stereotactic body radiation therapy solution which targets tumors non-invasively with precisely delivered, high doses of radiation that spare healthy tissue and minimize disruption to patients’ lives.
According to the company, the new CyberKnife M6 system can direct beams from a wider angle around the patient and provides a streamlined user interface for treatment delivery.
Accuray president and CEO Joshua H Levine said that the company developed the CyberKnife M6 series to meet the needs of every radiation oncology practice with efficient, accurate and flexible treatment options applicable to a wide variety of patients.
"On the heels of adoption in Europe, we are pleased to be working with Sir Charles Gairdner Hospital in Australia, where patients can now have the CyberKnife System as a radiation treatment option," Levine added.
The company has officially introduced the CyberKnife M6 system, a non-surgical option for many patients who have inoperable or surgically complex tumors, or who seek an alternative to surgery, in April 2014.